The ALS Association Research Program
The Leader in Global ALS Research
The ALS Association has committed more than $67 million to find effective treatments and a cure for Lou Gehrig’s Disease. Our global research effort has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS.
The ALS Association has funded significant research milestones in the fight against ALS, including:
- The groundbreaking discovery of a genetic abnormality that is, to date, the most common cause known of ALS and FTD.
- The recent exciting finding involved in familial ALS shows how two proteins work together to buttress the survival of motor neurons.
- Discovery of the ALS gene, SOD1, responsible for 20 percent of all inherited ALS cases.
- Discovery of ALS6 in 2009, a new gene responsible for about 5% of all inherited ALS cases.
- The first clinical trial of ISIS-SOD1, a new drug that specifically targets the SOD1 gene.
Latest News
Phase III Dex Trial Discussion
February 7, 2013In ALS, Neurons and Support Cells Change Each Other, for the Worse
February 4, 2013ALS Drug Development Gets FDA Hearing, Could See Push For Surrogate Markers
February 1, 2013The ALS Association worked with FDA to seek a public forum in which ALS patients can present their perspective on benefit/risk in development of drugs for their condition.
Reprogramming Neurons Shows They Can Take on New Identities
January 29, 2013For more information about our research program, please contact:
Bruijn-Yard Consultants, Medical Research
Lucie Bruijn, PhD
Chief Scientist
lucie@alsa-national.org
Tel: +1 727 412 0234
Fax: +1 727 499 9578
Mark Yard
Research Programs & Operations
mark@alsa-national.org
Tel: +1 203 641 1158
Fax: +1 727 499 9578
All written communications should be sent via e-mail, as an attachment to an e-mail or faxed.
More in this Section
Research ALS Today
The ALS Association's National Research Periodical provides in-depth coverage of current research projects and exciting clinical trials.





